United Therapeutics’ (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

Posted byZacks Equity Research Leave a comment on United Therapeutics’ (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics’ (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Leave a comment

Your email address will not be published. Required fields are marked *